Rybelsus Lawsuit: The Oral Semaglutide Tablet and Both GLP-1 Injury Tracks

Marin & MurphySuper Lawyers® 2014–2024(888) 348-2735

Ozempic (GLP-1) Lawsuit — Free Case Review

Which Medications — and Which Injuries — Qualify

Eligibility differs by drug and by injury track. Check yours against the current criteria in minutes.

No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone's injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state.

Did this happen to you — or someone you love?

Start your free case reviewTell us anyway

Answered 24/7 · Free & confidential · No fee unless there is a recovery. Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney's fee is a percentage of the gross recovery, calculated before expenses are deducted.

(888) 348-2735

Partners

Matthew T. Marin & Stefanie A. Murphy

Super Lawyers® honorees · American Association for Justice members

Ozempic inquiries get a personal review — and an honest answer either way, free and without obligation.

No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone's injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state. Do not stop, start, or change any prescribed medication because of anything on this page. Those decisions belong with your prescriber. Attorney Advertising.

Rybelsus is Novo Nordisk’s daily semaglutide tablet — the same active ingredient as Ozempic and Wegovy in pill form — and it is one of only three brands that currently fit both tracks of the GLP-1 litigation: the stomach-injury track (MDL 3094) and the NAION sudden vision-loss track (MDL 3163), both before Judge Karen S. Marston in the Eastern District of Pennsylvania. Marin & Murphy is currently accepting Ozempic (GLP-1) gastroparesis and NAION cases.

A pill, not a pen — and it counts the same

People who took Rybelsus often assume this litigation is not about them. It looks different from the injectables in every way a patient notices: a tablet every morning on an empty stomach, no pen, no needle, no refrigerator. But Rybelsus is semaglutide, the same molecule as Ozempic and Wegovy, and it is named alongside them in the court filings, the regulatory reviews, and the referral criteria. The delivery form does not change eligibility.

What matters is that the product was the brand-name prescription drug. Compounded or generic semaglutide — including oral or sublingual preparations sold by med spas and telehealth services — does not currently meet the criteria for either track. If you cannot tell from memory which you had, that is normal, and pharmacy records usually settle it.

Rybelsus fits both tracks

• Stomach-injury track (gastroparesis, gastric obstruction). The referral criteria are limited to brand-name semaglutide — Ozempic, Wegovy, or Rybelsus. Rybelsus qualifies. Mounjaro, Zepbound, and Trulicity do not meet these criteria for the stomach track.
• NAION vision-loss track. The criteria cover brand-name Ozempic, Wegovy, Rybelsus, Trulicity, Mounjaro, and Zepbound. Rybelsus qualifies here too.

That dual eligibility is not a technicality. It is the reason a Rybelsus user with a documented stomach injury and a Rybelsus user with a diagnosed NAION injury are on entirely different paths from the first question forward — different courts, different medical proof, different timelines.

Where Rybelsus cases are litigated

The Judicial Panel on Multidistrict Litigation created MDL 3094 on February 2, 2024, transferring 17 gastrointestinal-injury actions to the Eastern District of Pennsylvania. That court’s product list names Ozempic, Wegovy, Rybelsus, Trulicity, and Mounjaro, and Case Management Order No. 18 (August 23, 2024) defines the injuries in scope as gastroparesis, ileus and intestinal obstruction, cholecystitis, and severe nausea and vomiting.

NAION claims are not in that MDL. They were centralized separately as MDL 3163 on December 15, 2025 — 20 actions, same judge, different proceeding. New Jersey mirrored the split: its Supreme Court’s October 16, 2025 order designated two distinct multicounty litigations, one gastrointestinal and one NAION, both in Bergen County before Judge Gregg A. Padovano, expressly naming Rybelsus.

FDA adverse-event data for semaglutide

FDA’s FAERS database records these reports by active ingredient, so Rybelsus reports sit inside the semaglutide totals rather than in a separate brand bucket. As of the July 30, 2026 data refresh, FAERS held 82,911 total semaglutide reports and 36,179 serious reports, including 3,558 coded as impaired gastric emptying, 1,166 for intestinal obstruction, 632 for ileus, and 631 for optic ischaemic neuropathy — the term FAERS uses for NAION.

Reports submitted to FDA are not verified and do not establish causation; they are voluntary, can duplicate one another, and rise and fall with prescribing volume and news coverage. They are voluntary submissions, they can contain duplicates, and their volume tracks media and litigation attention as much as anything clinical.

What the data does show, directionally, is that the NAION reporting signal is concentrated in semaglutide products rather than in the tirzepatide or dulaglutide products, which is consistent with where the published research has focused. It does not establish relative risk between drugs.

What regulators concluded, and what your label said

On September 22, 2023, FDA required an ileus — intestinal blockage — warning be added to the semaglutide labeling as a postmarketing-identified risk. On June 6, 2025, the European Medicines Agency’s safety committee concluded that NAION is a very rare side effect of semaglutide medicines, naming Ozempic, Rybelsus, and Wegovy specifically, and recommended that European product information be updated to list it.

As of today, the United States label still does not carry a NAION warning. Whatever a patient could reasonably have known in this country, they could not have read it on the label, because it was not there.

Who may qualify

• Stomach injuries (gastroparesis or gastric obstruction): brand-name Rybelsus, Ozempic, or Wegovy; a gastroparesis diagnosis confirmed by a gastric emptying study, or gastric obstruction confirmed by objective testing; diagnosed while taking the medication or within about 30 days of stopping; an emergency-room visit or hospital admission; a diagnosis made before December 31, 2024; and age 75 or under at intake.
• NAION (sudden optic-nerve vision loss): brand-name Rybelsus, Ozempic, Wegovy, Trulicity, Mounjaro, or Zepbound; an actual NAION diagnosis made while taking the medication or after stopping; and some degree of permanent vision impairment.
• About the gastric emptying study. In August 2025 the judge overseeing MDL 3094 ruled that a gastroparesis claim must be supported by properly performed objective gastric-emptying testing rather than symptoms alone. That is a documentation requirement the court imposed on the cases; it is not a judgment about whether you are sick. Most people diagnosed with gastroparesis were never sent for that test. “I’m not sure what testing I had” is a legitimate answer and a good reason to talk to someone who can read your records.
• You are not suing your doctor. These are claims against the manufacturer, Novo Nordisk — not against the physician who prescribed a medication the label described as safe, and not against your pharmacy.

The honest posture, as of October 2026

There is no trial date and no bellwether pool in either MDL. The most significant ruling so far went against plaintiffs: on August 15, 2025 the court required objective gastric-emptying testing and excluded two plaintiff diagnostic experts. The most recent gate was a Rule 702 hearing held September 14 through 18, 2026 on general causation, preemption, and warning adequacy, and a summary-judgment motion on gastroparesis claims is pending.

In the NAION track, the court granted early cross-cutting motion practice on July 2, 2026 and appointed a special discovery master on July 21, 2026; Case Management Order No. 14 (August 27, 2026) set the expert schedule, with plaintiffs’ expert reports due March 26, 2027. Anyone telling you how or when this ends is guessing.

Common questions

Other GLP-1 medications: Wegovy, Mounjaro, Zepbound, Trulicity, and compounded semaglutide. The manufacturer: Novo Nordisk.